JP2011519359A - アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ - Google Patents

アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ Download PDF

Info

Publication number
JP2011519359A
JP2011519359A JP2011504527A JP2011504527A JP2011519359A JP 2011519359 A JP2011519359 A JP 2011519359A JP 2011504527 A JP2011504527 A JP 2011504527A JP 2011504527 A JP2011504527 A JP 2011504527A JP 2011519359 A JP2011519359 A JP 2011519359A
Authority
JP
Japan
Prior art keywords
sialylation
fsh
rfsh
recombinant fsh
sialic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011504527A
Other languages
English (en)
Japanese (ja)
Inventor
コッティンガム，イアン
プラクシン，ダニエル
ホワイト，リチャード，ボイド
Original Assignee
フェリング インターナショナル センター エス．アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011519359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by フェリング インターナショナル センター エス．アー． filed Critical フェリング インターナショナル センター エス．アー．
Publication of JP2011519359A publication Critical patent/JP2011519359A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011504527A 2008-04-16 2009-04-16 アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ Pending JP2011519359A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528 2008-04-25
EP08251528.9 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014262056A Division JP2015120696A (ja) 2008-04-16 2014-12-25 アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ

Publications (1)

Publication Number Publication Date
JP2011519359A true JP2011519359A (ja) 2011-07-07

Family

ID=39717519

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2011504527A Pending JP2011519359A (ja) 2008-04-16 2009-04-16 アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ
JP2014262056A Pending JP2015120696A (ja) 2008-04-16 2014-12-25 アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ
JP2016198588A Active JP6486310B2 (ja) 2008-04-16 2016-10-07 アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ
JP2017148823A Active JP6762916B2 (ja) 2008-04-16 2017-08-01 アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ
JP2019194476A Active JP7316905B2 (ja) 2008-04-16 2019-10-25 アルファ２，３－およびアルファ２，６－シアリル化を含む組換えｆｓｈ
JP2021175403A Pending JP2022031652A (ja) 2008-04-16 2021-10-27 アルファ２，３－およびアルファ２，６－シアリル化を含む組換えｆｓｈ
JP2023215339A Pending JP2024038000A (ja) 2008-04-16 2023-12-21 アルファ２，３－およびアルファ２，６－シアリル化を含む組換えｆｓｈ

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014262056A Pending JP2015120696A (ja) 2008-04-16 2014-12-25 アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ
JP2016198588A Active JP6486310B2 (ja) 2008-04-16 2016-10-07 アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ
JP2017148823A Active JP6762916B2 (ja) 2008-04-16 2017-08-01 アルファ２，３−およびアルファ２，６−シアリル化を含む組換えｆｓｈ
JP2019194476A Active JP7316905B2 (ja) 2008-04-16 2019-10-25 アルファ２，３－およびアルファ２，６－シアリル化を含む組換えｆｓｈ
JP2021175403A Pending JP2022031652A (ja) 2008-04-16 2021-10-27 アルファ２，３－およびアルファ２，６－シアリル化を含む組換えｆｓｈ
JP2023215339A Pending JP2024038000A (ja) 2008-04-16 2023-12-21 アルファ２，３－およびアルファ２，６－シアリル化を含む組換えｆｓｈ

Country Status (29)

Country Link
US (6) US8951967B2 (cg-RX-API-DMAC7.html)
EP (7) EP3098234B1 (cg-RX-API-DMAC7.html)
JP (7) JP2011519359A (cg-RX-API-DMAC7.html)
KR (5) KR102108377B1 (cg-RX-API-DMAC7.html)
CN (3) CN105906702A (cg-RX-API-DMAC7.html)
AR (1) AR071479A1 (cg-RX-API-DMAC7.html)
AU (5) AU2009237479B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910461B8 (cg-RX-API-DMAC7.html)
CA (1) CA2725257A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115413T1 (cg-RX-API-DMAC7.html)
DK (6) DK3144318T3 (cg-RX-API-DMAC7.html)
ES (5) ES2610277T3 (cg-RX-API-DMAC7.html)
FI (4) FI3098234T3 (cg-RX-API-DMAC7.html)
FR (3) FR17C1020I2 (cg-RX-API-DMAC7.html)
HR (5) HRP20241187T1 (cg-RX-API-DMAC7.html)
HU (9) HUE068565T2 (cg-RX-API-DMAC7.html)
IL (2) IL208538A (cg-RX-API-DMAC7.html)
LT (8) LT3045471T (cg-RX-API-DMAC7.html)
MX (3) MX2010011343A (cg-RX-API-DMAC7.html)
NO (4) NO2017025I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ588381A (cg-RX-API-DMAC7.html)
PL (6) PL3144318T3 (cg-RX-API-DMAC7.html)
PT (6) PT3098234T (cg-RX-API-DMAC7.html)
RU (3) RU2537268C2 (cg-RX-API-DMAC7.html)
SA (1) SA109300228B1 (cg-RX-API-DMAC7.html)
SI (6) SI4015527T1 (cg-RX-API-DMAC7.html)
TW (1) TWI488640B (cg-RX-API-DMAC7.html)
WO (1) WO2009127826A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007373B (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014522871A (ja) * 2011-08-08 2014-09-08 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
JPWO2013161958A1 (ja) * 2012-04-27 2015-12-24 Ｊｃｒファーマ株式会社 新規な発現ベクター
JP2019509728A (ja) * 2016-02-15 2019-04-11 ツェヴェック ファーマシューティカルズ ゲーエムベーハー ジアンテナ型ｎ−グリカンを有する組み換え糖タンパク質を産生する細胞株、それを使用する方法、及び組み換え糖タンパク質
JP2020515254A (ja) * 2017-03-29 2020-05-28 ツェヴェック ファーマシューティカルズ ゲーエムベーハー アンテナ型フコシル化が減少された組み換え糖タンパク質

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HRP20150968T4 (hr) 2010-09-29 2023-11-10 Ferring B.V. Pripravak za uporabu za liječenje neplodnosti
KR101898302B1 (ko) 2010-10-15 2018-09-13 제이씨알 파마 가부시키가이샤 당사슬의 비환원 말단이 만노오스 잔기인 당 단백질의 제조 방법
CA2831486A1 (en) * 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
ES2784625T3 (es) 2015-04-17 2020-09-29 Ferring Bv FSH para el tratamiento de la infertilidad
EP3313859B1 (en) 2015-06-26 2019-11-20 Ferring BV Methods of purification and/or viral inactivation
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
AR112541A1 (es) 2017-09-01 2019-11-06 Ferring Bv Composición para estimulación ovárica controlada con hef recombinante
EP3787667B1 (en) 2018-04-30 2025-03-26 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
US20250241993A1 (en) 2022-04-01 2025-07-31 Ferring B.V. Mixed protocol for treatment of infertility
US20250333466A1 (en) 2022-05-26 2025-10-30 Ferring B.V. Compositions and methods for treatment of infertility in males
AU2023302100A1 (en) 2022-07-08 2025-01-02 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
TW202504578A (zh) 2023-07-20 2025-02-01 荷蘭商輝凌責任有限公司 緩釋載藥微粒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011665A1 (en) * 1997-09-01 1999-03-11 Kirin Brewery Company, Limited Human thrombopoietin produced by established human cell lines, process for producing the same, and medicinal compositions containing the same
JP2005515974A (ja) * 2001-10-22 2005-06-02 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 卵胞形成のためのゴナドドロピン
JP2007515410A (ja) * 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド ＧｌｙｃｏＰＥＧ化卵胞刺激ホルモン

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
EP1176976B2 (en) 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
BR0213402A (pt) 2001-10-29 2004-10-13 Crucell Holland Bv Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero
CA2468957C (en) 2001-12-07 2011-07-12 Crucell Holland B.V. Methods of propagation of influenza virus in cell lines over expressing sialyl transferases
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
DK1711834T3 (da) 2004-02-04 2010-11-29 Centre Nat Rech Scient Fremgangsmåde til screening af glycoform-specifikke antistoffer
CN1926242B (zh) 2004-02-13 2013-01-16 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016575A1 (en) 2010-08-03 2012-02-09 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HRP20150968T4 (hr) 2010-09-29 2023-11-10 Ferring B.V. Pripravak za uporabu za liječenje neplodnosti
CA2831486A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
US20170035854A1 (en) 2014-04-18 2017-02-09 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011665A1 (en) * 1997-09-01 1999-03-11 Kirin Brewery Company, Limited Human thrombopoietin produced by established human cell lines, process for producing the same, and medicinal compositions containing the same
JP2005515974A (ja) * 2001-10-22 2005-06-02 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 卵胞形成のためのゴナドドロピン
JP2007515410A (ja) * 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド ＧｌｙｃｏＰＥＧ化卵胞刺激ホルモン

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FERTILITY AND STERILITY，２００４年 ８月，V82 NO.2，P348-357, JPN6015009482, ISSN: 0003025449 *
FLACK M R: "INCREASED BIOLOGICAL ACTIVITY DUE TO BASIC ISOFORMS IN RECOMBINANT HUMAN 以下備考", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. V79 NO.3, JPN5011001071, September 1994 (1994-09-01), pages 756 - 760, ISSN: 0002700831 *
HUMAN REPRODUCTION, 2000, 15(9), PP.1898-1902, JPN6013060593, ISSN: 0002700832 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291708B2 (en) 2011-08-08 2022-04-05 Ferring B.V. Human-derived recombinant FSH for controlled ovarian stimulation
US9694052B2 (en) 2011-08-08 2017-07-04 Ferring B.V. FSH composition and methods for controlled ovarian stimulation
JP2017141253A (ja) * 2011-08-08 2017-08-17 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
US10624953B2 (en) 2011-08-08 2020-04-21 Ferring B.V. Human-derived recombinant FSH for controlled ovarian stimulation
JP2020147600A (ja) * 2011-08-08 2020-09-17 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
JP2014522871A (ja) * 2011-08-08 2014-09-08 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
JP7309660B2 (ja) 2011-08-08 2023-07-18 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
JP2023134561A (ja) * 2011-08-08 2023-09-27 フェリング ベスローテン フェンノートシャップ 調節卵巣刺激のための組成物
JPWO2013161958A1 (ja) * 2012-04-27 2015-12-24 Ｊｃｒファーマ株式会社 新規な発現ベクター
JP2019509728A (ja) * 2016-02-15 2019-04-11 ツェヴェック ファーマシューティカルズ ゲーエムベーハー ジアンテナ型ｎ−グリカンを有する組み換え糖タンパク質を産生する細胞株、それを使用する方法、及び組み換え糖タンパク質
JP7110104B2 (ja) 2016-02-15 2022-08-01 ツェヴェック ファーマシューティカルズ ゲーエムベーハー ジアンテナ型ｎ－グリカンを有する組み換え糖タンパク質を産生する細胞株、それを使用する方法、及び組み換え糖タンパク質
JP2020515254A (ja) * 2017-03-29 2020-05-28 ツェヴェック ファーマシューティカルズ ゲーエムベーハー アンテナ型フコシル化が減少された組み換え糖タンパク質
US11193156B2 (en) 2017-03-29 2021-12-07 Cevec Pharmaceutical GmbH Recombinant glycoproteins with reduced antennary fucosylation

Also Published As

Publication number Publication date
PL3144318T3 (pl) 2021-02-08
AU2017204259B2 (en) 2017-08-17
HUE068565T2 (hu) 2025-01-28
US9771407B2 (en) 2017-09-26
AU2014203277A1 (en) 2014-07-24
EP3098234A1 (en) 2016-11-30
FR25C1025I1 (fr) 2025-09-19
AU2017225020A1 (en) 2017-09-28
JP2022031652A (ja) 2022-02-22
KR102108377B1 (ko) 2020-05-08
PT3045471T (pt) 2017-06-14
FI4015527T3 (fi) 2025-04-29
KR20160056960A (ko) 2016-05-20
PT2808340T (pt) 2016-11-21
DK3098234T3 (da) 2024-10-21
CA2725257A1 (en) 2009-10-22
RU2682270C2 (ru) 2019-03-18
JP6762916B2 (ja) 2020-09-30
EP2808340B1 (en) 2016-08-17
RU2537268C2 (ru) 2014-12-27
AU2017204258B2 (en) 2017-08-17
PT3098234T (pt) 2024-10-21
SI3144318T1 (sl) 2020-12-31
HUS1700024I1 (hu) 2017-06-28
PT2268666E (pt) 2014-06-25
US20180079794A1 (en) 2018-03-22
BRPI0910461B8 (pt) 2021-05-25
HRP20140535T1 (hr) 2014-07-18
NO2017025I1 (no) 2017-06-06
HRP20170958T1 (hr) 2017-09-22
PT4015527T (pt) 2025-04-10
US9546204B2 (en) 2017-01-17
IL208538A0 (en) 2010-12-30
EP4015527B1 (en) 2025-01-22
ES2610277T3 (es) 2017-04-26
RU2014141994A (ru) 2016-05-10
JP6486310B2 (ja) 2019-03-20
SI3098234T1 (sl) 2024-10-30
AU2009237479B2 (en) 2014-05-15
MX348622B (es) 2017-06-22
LT2808340T (lt) 2016-11-10
SI2268666T1 (sl) 2014-07-31
US20150065695A1 (en) 2015-03-05
HRP20241187T1 (hr) 2024-12-06
US8951967B2 (en) 2015-02-10
FR17C1020I1 (cg-RX-API-DMAC7.html) 2020-04-10
HUE033830T2 (en) 2018-01-29
PL2268666T3 (pl) 2014-08-29
EP2722339A1 (en) 2014-04-23
FIC20250003I1 (fi) 2025-01-15
LTPA2017029I1 (lt) 2017-10-10
HK1199039A1 (en) 2015-06-19
AU2014203277B2 (en) 2017-04-06
US20110105398A1 (en) 2011-05-05
TW200948378A (en) 2009-12-01
PL3098234T3 (pl) 2025-01-07
JP7316905B2 (ja) 2023-07-28
KR20190092608A (ko) 2019-08-07
HUE030652T2 (en) 2017-05-29
LT4015527T (lt) 2025-04-10
HUS1700025I1 (hu) 2017-06-28
EP2268666A1 (en) 2011-01-05
WO2009127826A1 (en) 2009-10-22
NZ588381A (en) 2012-05-25
CY1115413T1 (el) 2017-01-04
HRP20250313T1 (hr) 2025-05-09
US11952407B2 (en) 2024-04-09
AU2009237479A1 (en) 2009-10-22
AU2017204258A1 (en) 2017-07-20
HUS2500029I1 (hu) 2025-07-28
EP3144318B1 (en) 2020-09-23
JP2015120696A (ja) 2015-07-02
LT3045471T (lt) 2017-07-10
AR071479A1 (es) 2010-06-23
LTPA2017018I1 (lt) 2017-06-26
PL2808340T3 (pl) 2017-02-28
JP2020040956A (ja) 2020-03-19
LT3098234T (lt) 2024-09-10
ZA201007373B (en) 2011-06-29
FR17C1020I2 (fr) 2020-04-10
PL3045471T3 (pl) 2017-10-31
SA109300228B1 (ar) 2014-04-08
ES3023526T3 (en) 2025-06-02
HUE030652T4 (en) 2017-09-28
ES2468318T3 (es) 2014-06-16
KR20110005863A (ko) 2011-01-19
BRPI0910461A8 (pt) 2018-10-16
BRPI0910461A2 (pt) 2018-03-27
HUS2500008I1 (hu) 2025-02-28
US20240327487A1 (en) 2024-10-03
FR25C1003I1 (fr) 2025-02-28
DK2268666T3 (da) 2014-05-12
HK1146284A1 (en) 2011-05-20
BRPI0910461B1 (pt) 2021-02-23
ES2629392T3 (es) 2017-08-09
US20160347811A1 (en) 2016-12-01
KR20180095140A (ko) 2018-08-24
MX355457B (es) 2018-04-19
KR101622944B1 (ko) 2016-05-23
DK3144318T3 (da) 2020-12-07
EP2808340A1 (en) 2014-12-03
IL208538A (en) 2014-03-31
US10995128B2 (en) 2021-05-04
PT3144318T (pt) 2020-11-04
RU2010141908A (ru) 2012-05-27
EP3144318A1 (en) 2017-03-22
EP3098234B1 (en) 2024-07-31
AU2017204259A1 (en) 2017-07-20
NO2025006I1 (no) 2025-01-16
FI3098234T3 (fi) 2024-10-31
JP2018021037A (ja) 2018-02-08
RU2745557C1 (ru) 2021-03-29
RU2014141994A3 (cg-RX-API-DMAC7.html) 2018-05-28
NO2025032I1 (no) 2025-07-14
US20210332099A1 (en) 2021-10-28
SI2808340T1 (sl) 2016-12-30
HRP20161520T1 (hr) 2016-12-30
EP2268666B1 (en) 2014-03-12
EP4015527A1 (en) 2022-06-22
NO2017050I1 (no) 2017-09-28
DK4015527T3 (da) 2025-04-14
KR20170110741A (ko) 2017-10-11
LTPA2025525I1 (cg-RX-API-DMAC7.html) 2025-07-25
ES2989729T3 (es) 2024-11-27
EP3045471A1 (en) 2016-07-20
TWI488640B (zh) 2015-06-21
DK2808340T3 (en) 2016-12-05
JP2017060476A (ja) 2017-03-30
JP2024038000A (ja) 2024-03-19
CN105906702A (zh) 2016-08-31
AU2017225020B2 (en) 2019-11-14
IL230571A (en) 2015-11-30
SI3045471T1 (sl) 2017-07-31
LTPA2025505I1 (cg-RX-API-DMAC7.html) 2025-02-10
CN105906703A (zh) 2016-08-31
RU2745557C3 (ru) 2021-12-10
CN102066414A (zh) 2011-05-18
HUE071059T2 (hu) 2025-07-28
FIC20250025I1 (fi) 2025-07-11
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
AU2014203277C1 (en) 2017-07-27
EP3045471B1 (en) 2017-03-29
DK3045471T3 (en) 2017-06-26
HUS1700036I1 (hu) 2017-10-30
SI4015527T1 (sl) 2025-05-30

Similar Documents

Publication Publication Date Title
JP7316905B2 (ja) アルファ２，３－およびアルファ２，６－シアリル化を含む組換えｆｓｈ
HK40068781B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1227049B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1146284B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1197825A (en) Recombinant fsh including alpha 2,3-and alpha 2,6-sialylation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150108

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170202